With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Moderna may offer substantial upside, but it's essential to consider the associated risks. Since hitting their peak in late ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

The average short interest in the S&P 500 Health Care Index Sector (XLV) dipped slightly in July to 1.95% from 1.96% in June.

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Shares of the biotech Moderna were up on Wednesday, as the Trump administration’s shifting position on messenger RNA-based ...

Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid ...

Mixed options sentiment in Moderna (MRNA), with shares down 9c near $26.80. Options volume relatively light with 20k contracts traded and calls ...